Chinese biotech firm Baili Tianheng has moved its new antibody‑drug conjugate (ADC) into Phase II trials, marking the first domestic HER2‑bispecific antibody to earn a breakthrough‑therapy designation. The milestone reflects a broader shift in China’s pharmaceutical landscape: companies are no longer just selling “seedlings” (licensed compounds) abroad, but are forging deep, profit‑sharing partnerships with global giants. Notable examples include Innovent Biologics teaming up with Pfizer on four joint‑development projects and Hengrui Medicine collaborating with BMS on five innovative programs. Multinationals are now eager to tap early‑stage Chinese pipelines and technology platforms, turning China from a product exporter into an industry partner. At the same time, global biotech financing has rebounded dramatically in 2026. In May alone, investors completed 108 deals worth over $7.2 billion, while U.S. biotech IPOs raised $4.5 billion—five times the amount raised a year earlier. This flood of capital is fueling R&D and driving demand for Chinese drug assets, which have already secured $99.7 billion in overseas deals in the first half of the year, including eight of the world’s top‑10 transactions. Investor enthusiasm is also evident in the market: the Hong Kong Stock Connect Innovative Drug ETF (Huipu, 159570) attracted more than 600 million yuan of net inflows in just three days, underscoring confidence in China’s emerging drug innovators.
Read moreScientists in China and around the world are reshaping the fight against ultra‑rare neurological diseases. A new cceAAV gene‑therapy platform has moved into early clinical trials for spinal muscular atrophy, showing safety and efficacy on par with leading overseas products. At Xiangya Hospital, researchers combined whole‑genome sequencing, patient‑derived neurons, and transcriptomics to lift the diagnostic yield for infantile epileptic spasms by roughly 20%, paving the way for precise gene‑therapy selection. Crossing the blood‑brain barrier remains a major hurdle, but engineered AAV capsids, focused‑ultrasound with microbubbles, and direct brain injections are beginning to deliver drugs to the brain in Parkinson’s and Alzheimer’s trials. Meanwhile, the “N‑of‑1” model is turning personalized antisense‑oligonucleotide (ASO) therapies into reality: custom‑made drugs can now be designed in 4‑6 weeks and administered intrathecally, cutting the mutation‑to‑first‑dose timeline from years to under a year for conditions like ALS. Regulators are catching up. The FDA’s draft guidance now accepts N‑of‑1 trials as evidence, the EU’s PRIME scheme fast‑tracks ultra‑rare drugs, and China’s new technical guidelines open doors for small‑sample studies. Artificial‑intelligence tools coupled with multi‑omics biomarkers are slashing diagnostic delays, which in China average 4.3 years. Finally, a landmark 2025 study demonstrated prime‑editing repair of a childhood seizure‑causing gene in mouse brains, achieving 85 % correction after a single injection—signaling a shift from gene replacement to precise gene repair for countless rare brain disorders.
Read more